Soleno Therapeutics, Inc. (Nasdaq: SLNO), a pioneering biopharmaceutical company in the rare disease sector, has declared the launch of a significant public offering. The company is offering 3 million shares of its common stock to the public at $46.00 per share, with expectations to raise gross proceeds of around $138 million. This capital raise is…